The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
More top news
Isolated afternoon showers are likely over Scotland.
"I definitely get less money than a male in my situation would," she said. "Definitely."
Muscular Dystrophy UK said the lack of an option to label abusive tweets based on disability was preventing more reporting.